The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial.
 
Kent C. Shih
No Relationships to Disclose
 
Manish R. Patel
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
 
Nicholas A. Butowski
Consulting or Advisory Role - Abbvie; Genentech/Roche; Medicenna; Omniox
Speakers' Bureau - Genentech/Roche
Research Funding - Abbvie; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Medicenna; Merck; Merrimack; Tocagen
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; BeiGene; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; Hutchison MediPharma; Ignyta; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Merck; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Rgenix; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Takeda; Tarveda Therapeutics; Tarveda Therapeutics; Tesaro; Tocagen; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Sani Haider Kizilbash
No Relationships to Disclose
 
Suzanne Fields Jones
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medimmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
 
Jeffrey A. Bacha
Leadership - DelMar Pharmaceuticals
Stock and Other Ownership Interests - DelMar Pharmaceuticals
Patents, Royalties, Other Intellectual Property - DelMar Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - DelMar Pharmaceuticals
 
Dennis Brown
Leadership - DelMar Pharmaceuticals
Stock and Other Ownership Interests - DelMar Pharmaceuticals
Consulting or Advisory Role - DelMar Pharmaceuticals
Patents, Royalties, Other Intellectual Property - DelMar Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - DelMar Pharmaceuticals
 
Richard Stephen Schwartz
Consulting or Advisory Role - DelMar Pharmaceuticals
Travel, Accommodations, Expenses - DelMar Pharmaceuticals
 
Sarath Kanekal
Consulting or Advisory Role - DelMar Pharmaceuticals
Travel, Accommodations, Expenses - DelMar Pharmaceuticals
 
John C.I. Constant
No Relationships to Disclose
 
Howard A. Burris
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis